Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie Cuts Its Guidance on ImmunoGen Deal
12:20pm, Monday, 12'th Feb 2024
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
07:51am, Monday, 12'th Feb 2024
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The co
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
07:30am, Monday, 12'th Feb 2024
The healthcare industry can be a relatively stable place to invest for generating long-term wealth. AbbVie is dealing with the blow of losing Humira patent exclusivity, but there's more behind the bus
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
08:25am, Sunday, 11'th Feb 2024
AbbVie's next-gen immunology superstars are well on their way to replacing Humira. The company is also an excellent dividend stock.
How I Would Invest $1,000,000 And Live Of Dividends Forever
09:59pm, Saturday, 10'th Feb 2024
Reaching retirement and having enough capital to build a dividend money machine are dreams shared by many. With life expectancy on the rise, high yield alone is no longer sufficient; we need to plan f
3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying?
06:18pm, Thursday, 08'th Feb 2024
Investors know the phrase “let your winners run,” but it's easier said than done. The temptation to take profits off the table is often too great to ignore.
5 Dividend Aristocrats Signal Buy In February And 6 To Watch
05:26pm, Wednesday, 07'th Feb 2024
"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com. 67 Aristocrats, screened as of February 5, 2024 represen
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 06'th Feb 2024
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
7 Dividend Stocks Worth Holding for the Long Haul
09:11am, Tuesday, 06'th Feb 2024
Investing in dividend stocks is generally reserved for those who prefer steady returns and low volatility over the thrill of rapid potential gains. Investors saw tech stocks explode in 2023 as art
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
09:00am, Tuesday, 06'th Feb 2024
Dividend growth stocks have consistently been among the market's best performers for over a century. AbbVie is a top dividend growth stock that's going through a slow period, but its future looks brig
This is Why AbbVie (ABBV) is a Great Dividend Stock
12:46pm, Monday, 05'th Feb 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Abbvie: Why The 3.7% Yielder With 10% Annual Return Potential Remains One Of My Go-To Investments For Income And Growth
09:15am, Monday, 05'th Feb 2024
AbbVie has a yield of 3.7% and consistent dividend growth, making it a great investment for a wide range of investors. Despite concerns about the loss of its Humira patent, AbbVie remains in a fantast
Better Dividend Stock: Pfizer vs. AbbVie
08:54am, Monday, 05'th Feb 2024
Both Pfizer and AbbVie have been raising their dividend payments every year for more than a decade. Pfizer offers a higher dividend yield than AbbVie but it's growing at a slower pace.
3 Fabulous Dividend Stocks to Buy in February
05:50am, Sunday, 04'th Feb 2024
AbbVie is a Dividend King with plenty of growth potential left. Novartis offers investors a high dividend yield and strong prospects.
AbbVie Boosts Outlook for Two Key Drugs After Beating Profit, Sales Estimates
03:05pm, Friday, 02'nd Feb 2024
AbbVie Inc. (ABBV) shares traded near their all-time high Friday as the pharmaceutical company posted better-than-expected results and raised its sales forecast for two of its key medicines.
